Mind Medicine (mindmed) INC 8-K filings
8-K: MindMed Achieves Alignment with FDA on Phase 3 Strategy for MM120 in Generalized Anxiety Disorder
MindMed has successfully completed its End-of-Phase 2 meeting with the FDA, securing alignment on the Phase 3 development strategy for MM120 in treating Generalized Anxiety Disorder (GAD).
MindMed's 2024 Annual General and Special Meeting of Shareholders saw the election of six directors, the appointment of KPMG LLP as auditor, and the approval of the 2024 Employee Share Purchase Plan.
MindMed reported positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), along with a strong cash position of $252.3 million as of March 31, 2024.
MindMed will delist its common shares from Cboe Canada on April 10, 2024, to consolidate trading on Nasdaq.
MindMed has successfully priced a $175 million capital raise through a public share offering and a concurrent private placement, aimed at funding research and development and general corporate purposes.
MindMed's MM120 demonstrated significant and durable improvement in Generalized Anxiety Disorder symptoms in a Phase 2b trial, with a 7.7-point improvement over placebo at 12 weeks.
MindMed's MM120 program for generalized anxiety disorder (GAD) has been granted breakthrough therapy designation by the FDA, and a Phase 2b trial demonstrated significant and durable efficacy through 12 weeks.
MindMed reported positive topline Phase 2b data for MM120 in Generalized Anxiety Disorder (GAD) and provided a financial update for the year ended December 31, 2023.